Evidence map›Paper›PMID 33088326›Full record

ArticleResearch in pharmaceutical sciences2020

Efficacy of synbiotic supplementation in improving rheumatoid arthritis.

Farah Esmaeili, Mansour Salesi, Gholamreza Askari, Ali Esmaeilisharif, Mohammadreza Maracy, Hadi Karimzadeh, Behrokh Shojaie

Open access · goldAbstract read
In one paragraph

Article in Research in pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Farah EsmaeiliRheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Mansour SalesiRheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Gholamreza AskariDepartment of Community Nutrition, School of Nutrition and Food Sciences, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Ali EsmaeilisharifRheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Mohammadreza MaracyDepartment of Epidemiology and Biostatistics, School of Health, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Hadi KarimzadehRheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan, I.R. Iran.
Behrokh ShojaieDepartment of Biology, Faculty of Science, University of Isfahan, Isfahan, I.R. Iran.
Isfahan University of Medical Sciences · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeToday, improving rheumatoid arthritis (RA) as a chronic inflammatory disease is attributed to the proper status of the gut microbiota. Although some supplements containing beneficial live microorganisms (probiotics) can reduce inflammation by altering the bacterial composition of the gut, there is limited information on the effect of synbiotic (probiotics mixed with prebiotics) supplements on RA. Therefore, this study aimed to evaluate the anti-inflammatory effects of a synbiotic supplement as an adjuvant therapy in rheumatic patients. Moreover, for the first time, it was attempted to investigate whether addition of a synbiotic (1000 mg/day) to the combination of methotrexate and prednisolone increases the effectiveness of these antirheumatic drugs. EXPERIMENTAL APPROACH: Eligible patients (186 subjects) were randomly divided into two groups. Both groups received their standard routine antirheumatic drugs, methotrexate and prednisolone. Moreover, the first group received a daily oral synbiotic supplement (1000 mg) for 3 months while the second group received a placebo. Various parameters indicating RA status were evaluated at baseline (time 0) and 3 months after the treatment. FINDINGS /

resultsThe results showed the changes in the level of RA indicators, including tender joint count with a range of 0 to 28 joints, swollen joint count with a range of 0 to 28 joints, visual analog scale, erythrocyte sedimentation rate, CRP, and disease activity score based on 28 joints, after 3 months. CONCLUSION AND IMPLICATIONS: Overall, no significant differences in the measured parameters were observed between synbiotic and placebo groups probably due to the short duration of the treatment period, and it is suggested to extend the treatment period to six months.

Indexed as

Disease activityRheumatoid arthritisSynbiotics

Identifiers

PMID33088326
PMCPMC7540809
OpenAlexW3039497298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.